Answering important biological and chemical questions

As a component part of several projects we are focusing on the development of PET agents for brain imaging of important biological targets. One example project focuses on the development of a PET agent from CVN424, a potent and selective GPR6 inverse agonist (IAG) that was developed from a low potency screening hit. It was subsequently developed into a potent compound and is subsequently in clinical development to treat motor symptoms in Parkinsons disease (Figure 1).

Figure 1: CVN424 (top left) alongside other experimental PET agents of Martinostat (top right) and a novel HDAC inhibitor (bottom middle)